Lates News

Rongchang Biology stated on the interactive platform that the rise in Vor's stock price is beneficial for the company in two aspects. On one hand, it helps broaden its financing channels and strengthen its capital reserves to provide financial support for the smooth progress of the overseas global multicenter Phase III clinical trial of Taivosip. On the other hand, the increase in Vor's stock price, of which the company holds subscription warrants, will also increase the potential investment returns for the company.